Turn Therapeutics appoints Robert R. Redfield as chief scientific officer
Turn Therapeutics appointed Robert R. Redfield as chief scientific officer to advance scientific and clinical strategy for GX-03.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Turn Therapeutics appoints Robert R. Redfield as Chief Scientific Officer
Turn Therapeutics Inc. announced the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer. The company is a clinical-stage biotech focused on targeted, non-systemic therapies for inflammatory and infectious skin diseases.